Enveric Biosciences skyrockets on patent allowance for psychedelic-inspired molecules [Mugglehead Magazine]
Thursday, December 11, 2025 1 min read
Key Takeaway: Enveric Biosciences Inc has received a notice of allowance from the United States Patent and Trademark Office for its EVM301 non-psychoactive, psychedelic-inspired drugs. This patent allowance indicates that the agency views the application positively, paving the way for potential advancements in the company's drug development.
Price reaction · baseline $9.4544 (2025-12-11T16:14:00.000Z) · hit during market hours · 1 other ENVB headline(s) in the window, move may be shared
day 0 close
-42.5%
day 1
-42.6%
day 3 · peak
-44.6%
Market Sentiment Analysis
POSITIVE FACTORS
Enveric receives a patent allowance for EVM301.
The patent signals favorable views from the USPTO.
Potential for non-psychoactive psychedelic-inspired drugs.
Full Press Release Details
Enveric Biosciences Inc (NASDAQ: ENVB) will soon have a patent in hand for its EVM301 non-psychoactive, psychedelic-inspired drugs. The United States Patent and Trademark Office just gave Enveric a notice of allowance, thereby signalling that the agency views the patent application favourably.
Full Article >>
Frequently Asked Questions
What is EVM301?
EVM301 is a non-psychoactive, psychedelic-inspired drug developed by Enveric.
What did the USPTO grant Enveric?
The USPTO granted Enveric a notice of allowance for its patent application.
What does the patent allowance indicate?
The patent allowance indicates that the USPTO views the application favorably.